An Activin A/BMP2 chimera, AB215, blocks estrogen signaling via induction of ID proteins in breast cancer cells

BMC Cancer

Senyon Choe²  Witek Kwiatkowski²  Dong Kun Lee¹  Sun Young Shim¹  Jae Woo Jung³ 

[1]Joint Center for Biosciences, Songdo Global University Campus, 187 Songdo-dong, Incheon 406-840, Yeonsu-gu, Korea

[2]Salk Institute for Biological Studies, 10010 N. Torrey Pines RD, La Jolla, CA 92037, USA

[3]Currently at: Seoul National University, Interdisciplinary Graduate Program in Genetic Engineering, 1 Gwanak-ro, Seoul, Gwanak-gu, Korea

关键词: AB215;    Bio-better;    Inhibitor of DNA binding proteins;    Tamoxifen alternative;    Bone morphogenetic protein;    Transforming growth factor-β;    Estrogen receptor-positive breast cancer;   

Others  :  1125277
DOI  :  10.1186/1471-2407-14-549

 received in 2014-04-25, accepted in 2014-07-21,  发布年份 2014

【 摘 要 】

Background

One in eight women will be affected by breast cancer in her lifetime. Approximately 75% of breast cancers express estrogen receptor alpha (ERα) and/or progesterone receptor and these receptors are markers for tumor dependence on estrogen. Anti-estrogenic drugs such as tamoxifen are commonly used to block estrogen-mediated signaling in breast cancer. However, many patients either do not respond to these therapies (de novo resistance) or develop resistance to them following prolonged treatment (acquired resistance). Therefore, it is imperative to continue efforts aimed at developing new efficient and safe methods of targeting ER activity in breast cancer.

Methods

AB215 is a chimeric ligand assembled from sections of Activin A and BMP2. BMP2’s and AB215’s inhibition of breast cancer cells growth was investigated. In vitro luciferase and MTT proliferation assays together with western blot, RT_PCR, and mRNA knockdown methods were used to determine the mechanism of inhibition of estrogen positive breast cancer cells growth by BMP2 and AB215. Additionally in vivo xenograft tumor model was used to investigate anticancer properties of AB215.

Results

Here we report that AB215, a chimeric ligand assembled from sections of Activin A and BMP2 with BMP2-like signaling, possesses stronger anti-proliferative effects on ERα positive breast cancer cells than BMP2. We further show that AB215 inhibits estrogen signaling by inducing expression of inhibitor of DNA binding proteins (IDs). Specifically, we demonstrate that knockdown of ID proteins attenuates the anti-estrogen effects of AB215. Remarkably, we find that AB215 is more effective than tamoxifen in suppressing tumor growth in a xenograft model.

Conclusion

This study shows that IDs have profound role to inhibit estrogen signaling in ERα positive breast cancer cells, and that engineered TGF-beta ligands may have high therapeutic value.

【 授权许可】

   
2014 Jung et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Colditz GA: Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998, 90:814-823.
• [2]Helzlsouer KJ, Couzi R: Hormones and breast cancer. Cancer 1995, 76(10 Suppl):2059-2063.
• [3]Henderson BE, Ross R, Bernstein L: Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1988, 48:246-253.
• [4]Keen JC, Davidson NE: The biology of breast carcinoma. Cancer 2003, 97(3 Suppl):825-833.
• [5]Cerillo G, Rees A, Manchanda N, Reilly C, Brogan I, White A, Needham M: The oestrogen receptor regulates NFkappaB and AP-1 activity in a cell-specific manner. J Steroid Biochem Mol Biol 1998, 67:79-88.
• [6]Khan S, Abdelrahim M, Samudio I, Safe S: Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17beta-estradiol in breast cancer cells. Endocrinology 2003, 144:2325-2335.
• [7]Weldon CB, Elliott S, Zhu Y, Clayton JL, Curiel TJ, Jaffe BM, Burow ME: Regulation of estrogen-mediated cell survival and proliferation by p160 coactivators. Surgery 2004, 136:346-354.
• [8]Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M: Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000, 103:843-852.
• [9]Brouillet JP, Spyratos F, Hacene K, Fauque J, Freiss G, Dupont F, Maudelonde T, Rochefort H: Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: relative prognostic value versus total cathepsin D. Eur J Cancer Oxf Engl 1990 1993, 29A:1248-1251.
• [10]Stewart SS, Roldan JE, Lvov YM, Mills DK: Layer-by-Layer Adsorption of Biocompatible Polyelectrolytes onto Dexamethasone Aggregates. 28th Annu Int Conf IEEE Eng Med Biol Soc 2006 EMBS 06 2006, 1474-1477. http://ieeexplore.ieee.org/xpls/abs_all.jsp?arnumber=4462041&tag=1 webcite
• [11]Macías-Silva M, Hoodless PA, Tang SJ, Buchwald M, Wrana JL: Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J Biol Chem 1998, 273:25628-25636.
• [12]Ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Estevez M, Riddle DL, Ichijo H, Heldin CH, Miyazono K: Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem 1994, 269:16985-16988.
• [13]Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA: Novel regulators of bone formation: molecular clones and activities. Science 1988, 242:1528-1534.
• [14]Yoon BS, Lyons KM: Multiple functions of BMPs in chondrogenesis. J Cell Biochem 2004, 93:93-103.
• [15]Ghosh-Choudhury N, Ghosh-Choudhury G, Celeste A, Ghosh PM, Moyer M, Abboud SL, Kreisberg J: Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells. Biochim Biophys Acta 2000, 1497:186-196.
• [16]Waite KA, Eng C: BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum Mol Genet 2003, 12:679-684.
• [17]Jin H, Pi J, Huang X, Huang F, Shao W, Li S, Chen Y, Cai J: BMP2 promotes migration and invasion of breast cancer cells via cytoskeletal reorganization and adhesion decrease: an AFM investigation. Appl Microbiol Biotechnol 2012, 93:1715-1723.
• [18]Clement JH, Raida M, Sänger J, Bicknell R, Liu J, Naumann A, Geyer A, Waldau A, Hortschansky P, Schmidt A, Höffken K, Wölft S, Harris AL: Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. Int J Oncol 2005, 27:401-407.
• [19]Raida M, Clement JH, Leek RD, Ameri K, Bicknell R, Niederwieser D, Harris AL: Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res Clin Oncol 2005, 131:741-750.
• [20]Roldán M, Oliva F, Gónzalez del Valle MA, Saiz-Jimenez C, Hernández-Mariné M: Does green light influence the fluorescence properties and structure of phototrophic biofilms? Appl Environ Microbiol 2006, 72:3026-3031.
• [21]Yamamoto T, Saatcioglu F, Matsuda T: Cross-talk between bone morphogenic proteins and estrogen receptor signaling. Endocrinology 2002, 143:2635-2642.
• [22]Allendorph GP, Read JD, Kawakami Y, Kelber JA, Isaacs MJ, Choe S: Designer TGFβ superfamily ligands with diversified functionality. PLoS One 2011, 6:e26402.
• [23]Venkateshwar GP, Padhye MN, Khosla AR, Kakkar ST: Complications of exodontia: a retrospective study. Indian J Dent Res Off Publ Indian Soc Dent Res 2011, 22:633-638.
• [24]Keshamouni VG, Mattingly RR, Reddy KB: Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta. J Biol Chem 2002, 277:22558-22565.
• [25]Pinto A, Roldan R, Sollecito TP: Hypertension in children: an overview. J Dent Educ 2006, 70:434-440.
• [26]Roldán G, Delgado L, Musé IM: Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer. Cancer Biol Ther 2006, 5:505-510.
• [27]Roldan G, Ang RC: Overview of sleep disorders. Respir Care Clin N Am 2006, 12:31-54. viii
• [28]Brunnberg S, Pettersson K, Rydin E, Matthews J, Hanberg A, Pongratz I: The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription. Proc Natl Acad Sci U S A 2003, 100:6517-6522.
• [29]Pichon MF, Milgrom E: Clinical significance of the estrogen regulated pS2 protein in mammary tumors. Crit Rev Oncol Hematol 1993, 15:13-21.
• [30]Ravdin PM, De Moor CA, Hilsenbeck SG, Samoszuk MK, Vendely PM, Clark GM: Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients. Cancer Lett 1997, 116:177-183.
• [31]Perillo B, Sasso A, Abbondanza C, Palumbo G: 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 2000, 20:2890-2901.
• [32]Shang Y, Brown M: Molecular determinants for the tissue specificity of SERMs. Science 2002, 295:2465-2468.
• [33]Stoner M, Wormke M, Saville B, Samudio I, Qin C, Abdelrahim M, Safe S: Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins. Oncogene 2004, 23:1052-1063.
• [34]Allendorph GP, Vale WW, Choe S: Structure of the ternary signaling complex of a TGF-β superfamily member. Proc Natl Acad Sci 2006, 103:7643-7648.